Year All2024202320222021 Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C 07-09-2024 Zevra Therapeutics Expands Executive Leadership Team 06-25-2024 Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders 06-18-2024 Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting 06-03-2024 Zevra Therapeutics to Participate at Upcoming Investor Events 05-09-2024 Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates 05-08-2024 Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 05-01-2024 Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 04-29-2024 Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting 04-15-2024 Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility 04-10-2024
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C 07-09-2024
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders 06-18-2024
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting 06-03-2024
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 04-29-2024
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting 04-15-2024
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility 04-10-2024
